Boehringer Ingelheim

Boehringer Ingelheim

  • July 2020 •
  • 36 pages •
  • Report ID: 5780232 •
  • Format: PDF
PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Boehringer Ingelheim will see near-term growth, but will see long-term revenue declines because of fewer NMEs in its late-stage pipeline compared to its peers.
Key themes – [1] Upcoming label expansions for Jardiance should help to sustain recent robust revenue trends [2] Ofev should see continued growth in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease associated with systemic sclerosis (SSc-ILD) [3] Boehringer Ingelheim will see royalties from Skyrizi, which has already become a blockbuster product for AbbVie.

Model updates (20 May 2020)

Jardiance forecast adjusted higher
Glyxambi forecast removed due to Boehringer not providing brand-level revenue performance
Stiolto forecast removed due to Boehringer not providing brand-level revenue performance.

Model updates (6 August 2019)

Ofev forecast adjusted higher due to market share gains within IPF
Jardiance forecast adjusted higher due to strong growth.